Screened 2026-09-08 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Cigna holds its Accumulation at $275.83. The statistical read favours the sellers, held for 153 days.
As held on the ledger · 2026-09-08
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 153 days
Price at the screen
$275.83
Valuation
11.41 trailing · 8.24 forward price to earnings
Values screen
PASS· score 85.8
Beta
0.32
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
19.92%
Below 33%
Interest-bearing debt is just 19.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
2.24%
Below 33%
Cash held in interest-bearing accounts and securities is 2.2% of assets, under the one-third limit.
Pass
Receivables
23.08%
Below 49%
Money owed to the company is 23.1% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OPPORTUNITY: it trades at roughly a 45% discount to our $400.00 fair value, weak competitive moat, 6.70% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 45.0% margin of safety to the base estimate.
Third-party analyst targets: 24 covering, consensus Buy. The average target sits +24% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Health coverage priced like a fragile business
Picture a family in Ohio sorting pharmacy bills and specialist visits each month. Cigna moves that money through pharmacy benefits and employer plans, yet the shares sit at just 8.4 times forward earnings with a 42 percent gap to our 400 fair value. Revenue edges up 5 percent and return on equity holds at 16 percent, which is why the opportunity stands out.
Analysts see the same picture, with a 340 median target and a buy consensus from 24 firms. The business splits between Evernorth services and core healthcare coverage, both steady in a market that never stops needing claims processing.
The weak moat leaves room for rivals to chip away at margins that already run at only 2 percent, and any regulatory shift on drug pricing could squeeze results quickly. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CI trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-29Markdown · changed$274.41-5.2%Entry 11
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (24 analysts) rates it buy, with a mean price target of $341.
2026-07-30Markup$289.57+0.0%Entry 10
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (24 analysts) rates it strong buy, with a mean price target of $342. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-28Markup$289.57+0.0%Entry 9
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (24 analysts) rates it strong buy, with a mean price target of $342. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-27Markup$289.57+0.0%Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (24 analysts) rates it strong buy, with a mean price target of $342. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-26Markup$289.57+0.0%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (24 analysts) rates it strong buy, with a mean price target of $342. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-25Markup$289.57+2.9%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (24 analysts) rates it strong buy, with a mean price target of $342. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-24Markup$281.45+0.0%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (24 analysts) rates it strong buy, with a mean price target of $342. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-23Markup$281.45-2.8%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (24 analysts) rates it strong buy, with a mean price target of $342. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Markup$289.48+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (24 analysts) rates it strong buy, with a mean price target of $342.
2026-07-03Markup$289.48+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
